Caricamento...
Clinical Development of Immune Checkpoint Inhibitors
Recent progress in cancer immunotherapy has been remarkable. Most striking are the clinical development and approval of immunomodulators, also known as immune checkpoint inhibitors. These monoclonal antibodies (mAb) are directed to immune checkpoint molecules, which are expressed on immune cells and...
Salvato in:
| Pubblicato in: | Biomed Res Int |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Hindawi Publishing Corporation
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4486755/ https://ncbi.nlm.nih.gov/pubmed/26161407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/605478 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|